Inquiry Basket
Loading ......
Rift Valley fever virus (RVFV) is a formidable arthropod-borne pathogen that poses significant threats to livestock, human populations, and economies across Africa and the Arabian Peninsula . First identified in 1931 during an outbreak among sheep in Kenya's Rift Valley, this virus has demonstrated its capacity for devastating epizootics and epidemics, causing massive livestock losses and severe human disease . The expanding geographical range of its mosquito vectors, coupled with climate change and increasing global travel, has elevated RVFV from a regional concern to a global health security priority. Understanding the virology, epidemiology, pathogenesis, and molecular targets of this virus is essential for developing effective countermeasures against future outbreaks.
Figure 1. Morphological diversity of Rift Valley Fever Virus. (Calvo-Pinilla E, et al. 2020)
Rift Valley fever virus belongs to the genus Phlebovirus within the family Phenuiviridae of the order Bunyavirales . Its genome consists of three single-stranded, negative-sense RNA segments designated small (S), medium (M), and large (L) . This tripartite genome organization is characteristic of bunyaviruses and enables genetic reassortment when multiple strains coinfect the same cell, contributing to viral diversity and evolution .The S segment utilizes an ambisense coding strategy to produce two proteins: the nucleocapsid protein (N) and the non-structural protein (NSs) . The N protein encapsidates the viral RNA segments, forming ribonucleoprotein complexes essential for transcription and replication. The NSs protein serves as the primary virulence factor, functioning as a potent antagonist of the host innate immune response . The M segment encodes a polyprotein precursor that is proteolytically cleaved into the viral glycoproteins Gn and Gc, which form the spike-like projections on the viral envelope, along with two additional non-structural proteins (NSm1 and NSm2) of less defined function . The L segment encodes the viral RNA-dependent RNA polymerase (L protein), responsible for viral transcription and genome replication .
The replication cycle of RVFV follows the typical pattern of negative-sense RNA viruses, involving several key steps: attachment, entry, replication, transcription, assembly, and release. The cycle begins with the binding of the viral Gn and Gc glycoproteins to specific receptors on the host cell surface—primarily C-type lectin receptors (CLRs) and integrins expressed on epithelial cells, endothelial cells, and immune cells. This binding triggers endocytosis, with the virion being internalized into the host cell via clathrin-mediated endocytosis. Once inside the endosome, the acidic environment triggers conformational changes in the Gn and Gc glycoproteins, facilitating fusion of the viral envelope with the endosomal membrane and releasing the nucleocapsid into the cytoplasm. The viral RdRp (encoded by the L segment) then initiates transcription of the viral genome, producing positive-sense messenger RNAs (mRNAs) that are translated into viral proteins. For replication, the RdRp synthesizes negative-sense genomic RNA from positive-sense intermediates, which are then packaged into new nucleocapsids along with the N protein.
RVFV exists in a complex transmission cycle involving both vertical (transovarial) transmission in mosquito vectors and horizontal transmission between vertebrate hosts . More than 30 mosquito species, primarily within the Aedes and Culex genera, can transmit the virus . A key feature of RVFV ecology is the ability of infected Aedes mosquito eggs to survive desiccation for years, hatching during heavy rainfall or flooding to release infected mosquitoes that initiate outbreaks without requiring external viral introduction .
| Key Molecular Targets | Details |
| The JAK/STAT Signaling Pathway | Even if some interferon is produced, RVFV works to ensure cells cannot respond to it. The virus targets the JAK/STAT pathway, which is the primary signaling route for antiviral gene activation. By inhibiting JAK1 and TYK2 kinases, the virus prevents the phosphorylation of STAT1 and STAT2. Without the nuclear translocation of these proteins, the cell fails to produce Antiviral Stimulated Genes (ASGs), leaving it completely vulnerable to viral takeover. |
| Pro-inflammatory Cytokines: TNF and IL-6 | In the hemorrhagic form of the disease, the pathology is driven by an over-activation of the inflammatory response. High levels of TNF-alpha (TNF-α) and Interleukin-6 (IL-6) are found in fatal cases. |
| The Interferon Axis (IFN-β and IRF-3) | The most critical target of RVFV is the Type I Interferon (IFN) system. The viral NSs protein acts as a potent antagonist. It enters the host nucleus and prevents the assembly of the transcription factor complex for IFN-beta (IFN-β). |
Following transmission, RVFV initially replicates in regional lymph nodes before disseminating through the bloodstream to primary target organs, particularly the liver . Hepatocytes serve as the principal cellular targets, supporting massive viral replication that overwhelms hepatic function . The resulting hepatocellular necrosis releases liver enzymes into circulation and compromises synthetic and detoxification functions . Kupffer cells, the resident liver macrophages, also become infected and contribute to cytokine production and liver injury .The vascular endothelium represents another critical target, with viral infection increasing vascular permeability and contributing to hemorrhagic manifestations . In severe cases, disseminated intravascular coagulation develops, consuming clotting factors and exacerbating bleeding tendencies . The virus also demonstrates tropism for neurons and glial cells in the central nervous system, explaining neurological complications in some patients . The balance between viral replication kinetics and host immune responses ultimately determines disease outcome .
Laboratory diagnosis of RVFV relies on multiple complementary methods depending on the timing of sampling and available resources . During acute febrile illness, viral RNA detection by reverse transcription-polymerase chain reaction (RT-PCR) provides rapid, sensitive confirmation . Quantitative RT-PCR methods allow viral load determination, with higher levels correlating with severe disease . Virus isolation in cell culture or suckling mice remains the gold standard but requires high-containment biosafety level 3 or 4 facilities . Serological diagnosis detects IgM antibodies by enzyme-linked immunosorbent assay (ELISA) from day 5-7 of illness, confirming recent infection . IgG antibodies appear later and persist for years, indicating past exposure . Immunohistochemistry detects viral antigen in formalin-fixed tissues, valuable for retrospective diagnosis and epidemiological studies .
Rift Valley Fever Virus is a zoonotic pathogen of significant public health and veterinary importance, causing severe disease in animals and humans and posing a threat to food security and economic stability in endemic regions. Its ability to evade the host immune system, cause severe tissue damage, and be transmitted by mosquitoes makes it a challenging pathogen to control. This resource article provides a comprehensive overview of RVFV, covering its structure, classification, replication cycle, pathogenesis, key molecular targets (with distinct paragraphs for each target), detection methods, and current research directions. As research advances, further insights into viral-host interactions and the development of improved vaccines and therapies will be critical for controlling RVFV outbreaks and protecting the health of humans and animals.
Reference
| Target | Cat. No. | Product Name | Host | |
| RVFV | DAG-WT3701 | Recombinant RVFV glycoprotein G2 [His] | E. coli | Inquiry |
| RVFV | DAG-WT3702 | Recombinant RVFV glycoprotein G2 [His] | Baculovirus-Insect cells | Inquiry |
| RVFV NP | DAG-WT641 | Recombinant Rift Valley Fever Virus Nucleoprotein | E. coli | Inquiry |
| RVFV | DAGF-038 | Recombinant Rift Valley Fever Virus Glycoprotein (aa 691-1139)[His] | HEK293 | Inquiry |
| RVFV | DAGA-2013 | RVFV Glycoprotein(aa 154-583) [His] | E. coli | Inquiry |
| RVFV NP | DAG2321 | Recombinant RVFV Nucleo Protein (a.a. 1-245) [His] | HEK293 | Inquiry |
| RVFV NS | DAG2330 | Recombinant RVFV Nonstructural Protein (a.a. 1-265) [His] | E. coli | Inquiry |
| RVFV Gp | DAG2020 | Recombinant RVFV Glycoprotein (a.a. 691-1139) [His] | HEK293 | Inquiry |
| RVFV | DAGF-201 | Recombinant Rift Valley Fever Virus non-structural protein (RVFV-NS) [His] | E. coli | Inquiry |
Loading ......
